Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity

Evan M Hersh, M. G. Hanna, J. U. Gutterman, G. Mavligit, M. Yurconic, C. R. Gschwind

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Of 20 patients immunized with 100 μg formalin killed Rauscher leukemia virus (RLV) every 2 wk for 8 wk, 10 developed a significant antibody titer as measured by a radioimmunoprecipitation assay. Among the responders, the mean titer, taken as the reciprocal of the highest serial twofold dilution yielding 50% virus precipitation, was 1:354. Antibody first appeared 2 wk after immunization and reached a peak at 8 wk. Antibody responses were most vigorous in patients with melanoma and in those receiving BCG plus chemotherapy; responses were least vigorous in patients with other solid tumors or acute leukemia, and in those receiving chemotherapy without immunotherapy. Correlation was excellent between the antibody response and the development of delayed hypersensitivity to the virus (P=0.005) and between the antibody response and in vitro lymphocyte blastogenic response to an antigen solubilized from RLV infected cells (P=0.025). Extensive absorption studies indicated that sera from both immunized and non immunized subjects contained antimouse antibody. After in vivo absorption in mice, patients' postimmunization sera retained antiviral activity.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalJournal of the National Cancer Institute
Volume53
Issue number2
StatePublished - 1974
Externally publishedYes

Fingerprint

Rauscher Virus
Humoral Immunity
Vaccination
Antibody Formation
Antibodies
Radioimmunoprecipitation Assay
Viruses
Drug Therapy
Delayed Hypersensitivity
Mycobacterium bovis
Serum
Immunotherapy
Formaldehyde
Antiviral Agents
Melanoma
Immunization
Leukemia
Lymphocytes
Antigens
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hersh, E. M., Hanna, M. G., Gutterman, J. U., Mavligit, G., Yurconic, M., & Gschwind, C. R. (1974). Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity. Journal of the National Cancer Institute, 53(2), 327-333.

Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity. / Hersh, Evan M; Hanna, M. G.; Gutterman, J. U.; Mavligit, G.; Yurconic, M.; Gschwind, C. R.

In: Journal of the National Cancer Institute, Vol. 53, No. 2, 1974, p. 327-333.

Research output: Contribution to journalArticle

Hersh, EM, Hanna, MG, Gutterman, JU, Mavligit, G, Yurconic, M & Gschwind, CR 1974, 'Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity', Journal of the National Cancer Institute, vol. 53, no. 2, pp. 327-333.
Hersh, Evan M ; Hanna, M. G. ; Gutterman, J. U. ; Mavligit, G. ; Yurconic, M. ; Gschwind, C. R. / Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity. In: Journal of the National Cancer Institute. 1974 ; Vol. 53, No. 2. pp. 327-333.
@article{6eba5bdce06e414d9e444f81427bc3e7,
title = "Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity",
abstract = "Of 20 patients immunized with 100 μg formalin killed Rauscher leukemia virus (RLV) every 2 wk for 8 wk, 10 developed a significant antibody titer as measured by a radioimmunoprecipitation assay. Among the responders, the mean titer, taken as the reciprocal of the highest serial twofold dilution yielding 50{\%} virus precipitation, was 1:354. Antibody first appeared 2 wk after immunization and reached a peak at 8 wk. Antibody responses were most vigorous in patients with melanoma and in those receiving BCG plus chemotherapy; responses were least vigorous in patients with other solid tumors or acute leukemia, and in those receiving chemotherapy without immunotherapy. Correlation was excellent between the antibody response and the development of delayed hypersensitivity to the virus (P=0.005) and between the antibody response and in vitro lymphocyte blastogenic response to an antigen solubilized from RLV infected cells (P=0.025). Extensive absorption studies indicated that sera from both immunized and non immunized subjects contained antimouse antibody. After in vivo absorption in mice, patients' postimmunization sera retained antiviral activity.",
author = "Hersh, {Evan M} and Hanna, {M. G.} and Gutterman, {J. U.} and G. Mavligit and M. Yurconic and Gschwind, {C. R.}",
year = "1974",
language = "English (US)",
volume = "53",
pages = "327--333",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity

AU - Hersh, Evan M

AU - Hanna, M. G.

AU - Gutterman, J. U.

AU - Mavligit, G.

AU - Yurconic, M.

AU - Gschwind, C. R.

PY - 1974

Y1 - 1974

N2 - Of 20 patients immunized with 100 μg formalin killed Rauscher leukemia virus (RLV) every 2 wk for 8 wk, 10 developed a significant antibody titer as measured by a radioimmunoprecipitation assay. Among the responders, the mean titer, taken as the reciprocal of the highest serial twofold dilution yielding 50% virus precipitation, was 1:354. Antibody first appeared 2 wk after immunization and reached a peak at 8 wk. Antibody responses were most vigorous in patients with melanoma and in those receiving BCG plus chemotherapy; responses were least vigorous in patients with other solid tumors or acute leukemia, and in those receiving chemotherapy without immunotherapy. Correlation was excellent between the antibody response and the development of delayed hypersensitivity to the virus (P=0.005) and between the antibody response and in vitro lymphocyte blastogenic response to an antigen solubilized from RLV infected cells (P=0.025). Extensive absorption studies indicated that sera from both immunized and non immunized subjects contained antimouse antibody. After in vivo absorption in mice, patients' postimmunization sera retained antiviral activity.

AB - Of 20 patients immunized with 100 μg formalin killed Rauscher leukemia virus (RLV) every 2 wk for 8 wk, 10 developed a significant antibody titer as measured by a radioimmunoprecipitation assay. Among the responders, the mean titer, taken as the reciprocal of the highest serial twofold dilution yielding 50% virus precipitation, was 1:354. Antibody first appeared 2 wk after immunization and reached a peak at 8 wk. Antibody responses were most vigorous in patients with melanoma and in those receiving BCG plus chemotherapy; responses were least vigorous in patients with other solid tumors or acute leukemia, and in those receiving chemotherapy without immunotherapy. Correlation was excellent between the antibody response and the development of delayed hypersensitivity to the virus (P=0.005) and between the antibody response and in vitro lymphocyte blastogenic response to an antigen solubilized from RLV infected cells (P=0.025). Extensive absorption studies indicated that sera from both immunized and non immunized subjects contained antimouse antibody. After in vivo absorption in mice, patients' postimmunization sera retained antiviral activity.

UR - http://www.scopus.com/inward/record.url?scp=0016237196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016237196&partnerID=8YFLogxK

M3 - Article

C2 - 4858406

AN - SCOPUS:0016237196

VL - 53

SP - 327

EP - 333

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -